Blood Group Typing Market Global Market Report 2024

Blood group typing is a method employed to determine an individual's blood type, facilitating safe blood donation or transfusion.

Key types of blood group typing include antibody screening, cross-matching tests, ABO tests, antigen typing, and human leukocyte antigen (HLA) typing. Antibody screening tests are conducted in clinical laboratories or blood banks to identify unexpected antibodies, such as alloantibodies, in the serum related to non-ABO blood group antigens. Cross-matching tests are integral to blood compatibility testing before transfusions. HLA typing, a genetic test, identifies variations in immune system proteins, commonly used for matching patients and donors in bone marrow or cord blood transplants. ABO tests categorize blood types into A, B, AB, or O. Antigen tests, utilizing immunoassays, detect specific viral antigens and are employed in the diagnosis of respiratory pathogens like influenza viruses. Products used for blood group typing include instruments, reagents, and kits, employing techniques such as serology tests and molecular tests. Blood group typing finds application in hospital-based laboratories, independent laboratories, and blood banks.

The blood group typing market research report is one of a series of new reports that provides blood group typing market statistics, including blood group typing industry global market size, regional shares, competitors with a blood group typing market share, detailed blood group typing market segments, market trends and opportunities, and any further data you may need to thrive in the blood group typing industry. This blood group typing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The blood group typing market size has grown rapidly in recent years. It will grow from $2.76 billion in 2023 to $3.15 billion in 2024 at a compound annual growth rate (CAGR) of 14.1%. The growth observed during the historical period can be attributed to several factors, including the expansion of blood donation drives, the aging population, increased development of healthcare infrastructure, and a rise in clinical trials.

The blood group typing market size is expected to see rapid growth in the next few years. It will grow to $5.18 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The anticipated growth in the forecast period can be attributed to factors such as the increasing demand for blood and blood-related products, a rising prevalence of chronic diseases, a surge in road accidents, and an overall increase in healthcare spending. Key trends expected during this period include the adoption of automation and high-throughput systems, enhanced data integration capabilities, the implementation of public health initiatives, and continuous technological innovations within the field.

The blood group typing market experienced growth during the historic period, driven by a notable increase in the number of blood donations and transfusions. Various non-profit organizations, government entities, and agencies have been actively promoting the significance of blood donations through awareness campaigns. This surge in blood donations has led to an augmented demand for blood group typing, enabling donors to ascertain their blood type. As reported by the World Health Organization (WHO) in 2022, high-income nations, constituting 16% of the global population, contribute 40% of the 118.5 million worldwide blood donations. Notably, the distribution of blood transfusions varies, with children under five years receiving up to 54% in low-income nations, while those over 60 account for 76% in high-income countries. The upswing in blood donations and transfusions has thus been a significant factor propelling the growth of the blood typing market.

In the blood group typing market, technological advancements, particularly the adoption of automated technologies, have gained substantial traction. Key market players are actively introducing innovative tests based on advanced techniques, delivering results with reduced turnaround time, heightened accuracy, and enhanced efficiency. A case in point is the introduction of Immediate Spin Crossmatch (ISXM) by Ortho Clinical Diagnostics, a prominent U.S.-based in vitro diagnostics company, in September 2021. ISXM, a serological test utilized in blood transfusions, aids in identifying ABO blood type mismatches between donor red blood cells and recipient serum or plasma. This addition to Ortho's automated testing offering exemplifies the industry's commitment to leveraging cutting-edge technologies to meet evolving demands in the blood group typing market.

Prominent players in the blood gas and electrolyte analyzer market are directing their efforts toward the development of innovative products, exemplified by the ABO and RhD Solid-Phase Blood Grouping Kit, aimed at enhancing their offerings for existing consumers. This diagnostic instrument utilizes solid-phase technology to detect ABO blood type system A/B antigen and Rh blood group system D antigen in a clean fingerprick blood sample or anticoagulated blood. The ABO and RhD Solid-Phase Blood Grouping Kit, stable at room temperature, serves multiple purposes, including ABO and RhD blood group detection, prenatal testing, and assessing the risk of HDFN and ABO incompatibility. In February 2022, lnTec PRODUCTS, INC., a China-based manufacturer specializing in blood grouping kits and infectious disease diagnostics, launched the Notice-2nd Generation ABO and RhD Solid-Phase Blood Grouping Kit. This second-generation product retains the benefits of its predecessor while introducing additional features, such as improved affordability and redesigned cassettes/strips for faster and easier use. With just one drop of whole blood (15 μl), results can be obtained in 2 minutes, and every cassette or strip now includes both negative and positive internal checks, available in cassette and strip formats.

In March 2023, Werfen, S.A., a Spain-based company operating in blood group typing, hemostasis, and transfusion, completed the acquisition of Immucor Inc. for approximately US$2 billion. This strategic move expanded Werfen's position as a reference business in the specialized diagnostics market and broadened its diagnostic solutions for hospitals and clinical laboratories. The acquisition integrated Immucor Inc., a U.S.-based company specializing in blood group typing, into Werfen's portfolio, strengthening the company's range by adding Transfusion and Transplant product lines to its existing Hemostasis, Acute Care, and Autoimmunity business lines. The acquisition is a testament to Werfen's commitment to enhancing its capabilities and offerings in the blood gas and electrolyte analyzer market.

Major companies operating in the blood group typing market market include Grifols S.A., Bio-Rad Laboratories Inc., Immucor Inc., Ortho-Clinical Diagnostics Inc., Quotient Limited, B. Braun Melsungen AG, AXO Science SAS, Agena Bioscience Inc., Merck KGaA, Beckman Coulter Inc., Sucuri Inc., Rapid Labs Ltd., Day Medical SA, Novacyt Group, Chemtrade Logistics Income Fund, DIAGAST SAS, Thermo Fisher Scientific Inc., One Lambda Inc., Tulip Diagnostics (P) Ltd., Guangzhou Wondfo Biotech Co. Ltd., Mesa Laboratories Inc., Hemaxis Inc., ZenTech S.A., Hemogenyx Pharmaceuticals PLC, Lifespan Diagnostics LLC, TECOmedical AG, Blood Systems Inc., Japan Blood Products Organization, Medion Diagnostics GmbH, BioMedomics Inc., DiaSorin S.p.A., Grifols Diagnostic Solutions Inc., Hemo bioscience Inc.

North America was the largest region in the blood group typing market in 2023. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the blood group typing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the blood group typing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.

The blood group typing market consists of sale of serology reagents, gel systems, lateral flow rapid technology, and blood group genotyping products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.